Disease on EC 1.1.1.B40 - 11beta-hydroxysteroid dehydrogenase (NAD+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
11beta-hydroxysteroid dehydrogenase (nad+) deficiency
11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease.
Abnormalities of aldosterone synthesis and action in children.
Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation.
Cellular selectivity of aldosterone action: role of 11 beta-hydroxysteroid dehydrogenase.
Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families.
Endocrine causes of hypertension.
Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase.
Fatal, low renin hypertension associated with a disturbance of cortisol metabolism.
Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.
Heterogeneity of urinary steroid profiles in children with adrenocortical tumors.
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess.
Renin-Independent hypermineralocorticoidism.
Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome.
[11 beta-Hydroxysteroid dehydrogenase deficiency]
11beta-hydroxysteroid dehydrogenase deficiency
Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism.
Acidosis
Effects of changes in dietary intake of sodium and potassium and of metabolic acidosis on 11beta-hydroxysteroid dehydrogenase activities in rat kidney.
ACTH Syndrome, Ectopic
Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.
Adenoma
Cortisol-secreting adrenal adenomas express 11beta-hydroxysteroid dehydrogenase type-2 gene yet possess low 11beta-HSD2 activity.
Human adrenal cortex and aldosterone secreting adenomas express both 11beta-hydroxysteroid dehydrogenase type 1 and type 2 genes.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
Adrenal Hyperplasia, Congenital
Effect of hypercortisolism and ACTH on the metabolism of cortisol.
Hyper- and hypoaldosteronism.
Renin-Independent hypermineralocorticoidism.
Alkalosis
Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.
Asthma
A novel 11 beta-hydroxysteroid dehydrogenase inhibitor contained in saiboku-to, a herbal remedy for steroid-dependent bronchial asthma.
Magnolol stimulates steroidogenesis in rat adrenal cells.
Atherosclerosis
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Atrial Fibrillation
[Atrial 11beta-hydroxysteroid dehydrogenase type 2 expression in rheumatic heart disease patients with or without atrial fibrillation]
[Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases]
beta-carotene 3-hydroxylase deficiency
Hyper- and hypoaldosteronism.
Brain Ischemia
11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia.
Breast Neoplasms
Expression of the 11beta-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells.
Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells.
Carcinogenesis
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Carcinoma
Expression of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas.
Heterogeneity of urinary steroid profiles in children with adrenocortical tumors.
Cardiomegaly
Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation.
Cerebrovascular Disorders
11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia.
Cholestasis
Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis.
Choriocarcinoma
Analysis of the promoter of the NAD+ dependent 11 beta-hydroxysteroid dehydrogenase (HSD11K) gene in JEG-3 human choriocarcinoma cells.
Effect of cadmium on cortisol production and 11beta-hydroxysteroid dehydrogenase 2 expression by cultured human choriocarcinoma cells (JEG-3).
Regulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity and mRNA in human choriocarcinoma cells.
Colitis
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Colitis, Ulcerative
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Colonic Neoplasms
Can licorice lick colon cancer?
Colorectal Neoplasms
Expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer.
Cushing Syndrome
11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.
Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.
Effect of glucocorticoid excess on the cortisol/cortisone ratio.
Endocrine causes of hypertension.
Human kidney 11 beta-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin?
Renin-Independent hypermineralocorticoidism.
[Decreased activity of 11-beta-hydroxysteroid dehydrogenase in patients with Cushing's syndrome]
Diabetes Mellitus
Evaluation of hepatic 11 beta-hydroxysteroid dehydrogenase activity by cortisone acetate test in young adults with diabetes mellitus type 1.
Diabetes Mellitus, Type 2
Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
Eczema
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid.
Endocrine System Diseases
Endocrine causes of hypertension.
Endometrial Neoplasms
Modulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity in Ishikawa cells is associated with changes in cellular proliferation.
Fetal Growth Retardation
Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation.
Corticotropin-releasing hormone stimulates expression of leptin, 11beta-HSD2 and syncytin-1 in primary human trophoblasts.
Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11{beta}-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.
Genetic Diseases, Inborn
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Granuloma
11beta-hydroxysteroid dehydrogenases are regulated during the pulmonary granulomatous response to the mycobacterial glycolipid trehalose-6,6'-dimycolate.
Heart Failure
Inhibitors of 11 beta-hydroxysteroid dehydrogenase and 5 beta-steroid reductase in urine from patients with congestive heart failure.
Hyperaldosteronism
Endocrine causes of hypertension.
[Hypokalemia without arterial hypertension by licorice poisoning]
Hyperandrogenism
5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Hyperglycemia
Glucocorticoid "programming" and PTSD risk.
Hypertension
11 beta-hydroxysteroid dehydrogenase (11 beta-HSD-II) activity in human placenta: its relationship to placental weight and birth weight and its possible role in hypertension.
11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.
11 beta-Hydroxysteroid dehydrogenase activity in hypertension and renal disease.
11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
11 beta-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial Hypertension. Diagnosis and therapeutic approach in two young brothers.
11 beta-Hydroxysteroid dehydrogenase: a link between the dysregulation of cortisol metabolism and hypertension.
11beta-hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension.
A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Association between a variant in the 11 beta-hydroxysteroid dehydrogenase type 2 gene and primary hypertension.
Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives.
Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families.
Corticosteroid hypertension.
Corticosteroids in essential hypertension: multiple candidate loci and phenotypic variation.
Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics.
Cortisol, hypertension and obesity: the role of 11 beta-hydroxysteroid dehydrogenase.
Decreased activity of 11 beta-hydroxysteroid dehydrogenase in mesenteric arteries of Dahl salt-sensitive rats.
Defects in cortisol metabolism causing low-renin hypertension.
Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.
Effect of carbenoxolone on glucocorticoid metabolism and Na transport in toad bladder.
Endocrine causes of hypertension.
Endogenous 11 beta-hydroxysteroid dehydrogenase inhibitors and their role in glucocorticoid Na+ retention and hypertension.
Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertension.
Endogenous renal 11 beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension.
Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase.
Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension.
Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11{beta}-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.
Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks.
Glucocorticoid "programming" and PTSD risk.
Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.
Haemodynamic and metabolic effects of carbenoxolone in normal subjects and patients with renal impairment.
Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11?-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
Investigation of the mechanism of hypertension in apparent mineralocorticoid excess.
Licorice-induced hypertension and common variants of genes regulating renal sodium reabsorption.
Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess.
Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
Placental 11 beta-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies.
Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension.
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite.
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2.
The 11 beta-OHSD inhibitor, carbenoxolone, enhances Na retention by aldosterone and 11-deoxycorticosterone.
The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension.
The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero.
The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension.
The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.
[11 beta-hydroxysteroid dehydrogenase type 2 activity in Chilean patients with hypertension]
[Aldosterone and 11 beta-hydroxysteroid dehydrogenase: role in arterial hypertension]
[Endocrine hypertension]
[Hypokalemia without arterial hypertension by licorice poisoning]
Hypoaldosteronism
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Hypokalemia
A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics.
Inhibition of 11 beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds.
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2.
Infection
Active catabolism of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase in vivo is a necessary requirement for natural resistance to infection with Listeria monocytogenes.
Infertility
11 beta-Hydroxysteroid dehydrogenase enzyme activity in granulosa cells derived from ovarian follicles of in vitro fertilization patients.
Inflammatory Bowel Diseases
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
The metabolic syndrome X and peripheral cortisol synthesis.
The polygenetically inherited metabolic syndrome of WOKW rats is associated with insulin resistance and altered gene expression in adipose tissue.
Kidney Failure, Chronic
Role of 11beta-hydroxysteroid dehydrogenase 2 renal activity in potassium homeostasis in rats with chronic renal failure.
Leukemia
Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
Liddle Syndrome
Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Liver Cirrhosis
Biphasic changes of epithelial sodium channel abundance and trafficking in common bile duct ligation-induced liver cirrhosis.
Down-regulation of hepatic and renal 11 beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis.
Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis.
Liver Diseases
11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease.
Malnutrition
Fetal exposure to excess glucocorticoid is unlikely to explain the effects of periconceptional undernutrition in sheep.
Mineralocorticoid Excess Syndrome, Apparent
Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone.
[Liquorice-induced hypertension and hypokalaemia].
Neoplasm Metastasis
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Neoplasms
11 beta-hydroxysteroid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms.
11beta-Hydroxysteroid dehydrogenase types 1 and 2 are up- and downregulated in cortisol-secreting adrenal adenomas.
Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP.
Renin-Independent hypermineralocorticoidism.
Nephrotic Syndrome
Increased apical targeting of renal ENaC subunits and decreased expression of 11betaHSD2 in HgCl2-induced nephrotic syndrome in rats.
Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 is not responsible for sodium retention in nephrotic rats.
Obesity
11 beta-Hydroxysteroid dehydrogenase activity in hypothalamic obesity.
11-Beta hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity.
Cortisol, hypertension and obesity: the role of 11 beta-hydroxysteroid dehydrogenase.
Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Obesity, Abdominal
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women.
The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis.
Obesity, Morbid
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Osteoporosis
The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis.
Osteosarcoma
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Ovarian Neoplasms
Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
Pheochromocytoma
Endocrine causes of hypertension.
Pituitary Neoplasms
Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation.
Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors.
Polycystic Ovary Syndrome
5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Pre-Eclampsia
11 beta-Hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells.
Prostatic Neoplasms
11 beta-Hydroxysteroid dehydrogenase and tissue specificity of androgen action in human prostate cancer cell LNCaP.
Psoriasis
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid.
Respiratory Distress Syndrome, Adult
Increased expression of 11 beta-hydroxysteroid dehydrogenase type 2 in the lungs of patients with acute respiratory distress syndrome.
Rickets
Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome.
Stillbirth
Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
Vaccinia
Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus.